Matches in Wikidata for { <http://www.wikidata.org/entity/Q79109797> ?p ?o ?g. }
Showing items 1 to 50 of
50
with 100 items per page.
- Q79109797 description "assaig clínic" @default.
- Q79109797 description "clinical trial" @default.
- Q79109797 description "clinical trial" @default.
- Q79109797 description "clinical trial" @default.
- Q79109797 description "clinical trial" @default.
- Q79109797 description "ensaio clínico" @default.
- Q79109797 description "ensayo clínico" @default.
- Q79109797 description "ensayu clínicu" @default.
- Q79109797 description "essai clinique" @default.
- Q79109797 description "klinisch onderzoek" @default.
- Q79109797 description "клінічне випробування" @default.
- Q79109797 name "A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Ce" @default.
- Q79109797 name "A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Ce" @default.
- Q79109797 type Item @default.
- Q79109797 label "A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Ce" @default.
- Q79109797 label "A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Ce" @default.
- Q79109797 prefLabel "A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Ce" @default.
- Q79109797 prefLabel "A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Ce" @default.
- Q79109797 P1050 Q79109797-FE5B8659-8499-431A-A4F2-EE8CFF83C7C4 @default.
- Q79109797 P1132 Q79109797-89D3AA9B-5426-45DC-A4A8-BDCB2873091F @default.
- Q79109797 P1476 Q79109797-42497910-1F05-4537-987B-E081CEB94524 @default.
- Q79109797 P17 Q79109797-2DAF8B0B-2DE6-4BCF-B303-93F8D1896FE5 @default.
- Q79109797 P17 Q79109797-791F7E44-0285-42E1-8ECD-A5CC0A3E9346 @default.
- Q79109797 P17 Q79109797-C3AC71D1-AEBE-4D54-96D4-A5EFFD9A3F9D @default.
- Q79109797 P17 Q79109797-DBC03B6F-1929-4E89-9EBC-2DF5770B3DFA @default.
- Q79109797 P2899 Q79109797-7AEEEA51-2DD3-4727-8525-051C29578413 @default.
- Q79109797 P3098 Q79109797-2C91805F-5ECA-4746-B33E-EE48367B2122 @default.
- Q79109797 P31 Q79109797-61FBF4C6-949E-45B6-8BB1-0124CDE91FF1 @default.
- Q79109797 P4844 Q79109797-C6402D0C-E581-42CC-9B69-C00E99AEB6A0 @default.
- Q79109797 P580 Q79109797-BB11BCFB-EEB3-4A2E-91AC-7CB9CF0F1BE2 @default.
- Q79109797 P582 Q79109797-D91DE69E-9210-4F7C-B7F2-9E193EF88C00 @default.
- Q79109797 P6099 Q79109797-808C61F7-0712-4E5F-A18A-F8824CBEBC16 @default.
- Q79109797 P8363 Q79109797-C8F481B0-89E6-479A-93E5-638442DF5835 @default.
- Q79109797 P859 Q79109797-7234E2A6-A2AD-4282-ABC0-41E007AB10ED @default.
- Q79109797 P1050 Q208414 @default.
- Q79109797 P1132 "+216" @default.
- Q79109797 P1476 "A Phase III, Open-Label, Multicenter, Randomized, Study Evaluating the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab Plus Gemcitabine Plus Oxaliplatin (R-GEMOX) Versus R-GEMOX in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma" @default.
- Q79109797 P17 Q145 @default.
- Q79109797 P17 Q183 @default.
- Q79109797 P17 Q29 @default.
- Q79109797 P17 Q30 @default.
- Q79109797 P2899 "+18" @default.
- Q79109797 P3098 "NCT04182204" @default.
- Q79109797 P31 Q30612 @default.
- Q79109797 P4844 Q412323 @default.
- Q79109797 P580 "2019-11-29T00:00:00Z" @default.
- Q79109797 P582 "2023-04-29T00:00:00Z" @default.
- Q79109797 P6099 Q42824827 @default.
- Q79109797 P8363 Q78089383 @default.
- Q79109797 P859 Q212646 @default.